Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Faster pace than expected, Immunicum completes treatment of the last patient in its kidney cancer vaccine phase I/II-study already in August
Immunicum AB (publ) today announced that the last scheduled patient in the Company's phase I/II study in metastatic renal cancer has received the concluding dose of the cancer vaccine INTUVAX®.
Help employers find you! Check out all the jobs and post your resume.
Faster pace than expected, Immunicum completes treatment of the last patient in its kidney cancer vaccine phase I/II-study already in August
Immunicum AB (publ) today announced that the last scheduled patient in the Company's phase I/II study in metastatic renal cancer has received the concluding dose of the cancer vaccine INTUVAX®.
Help employers find you! Check out all the jobs and post your resume.
